Aluminum-induced osteogenesis in osteopenic rats with normal renal function.
Previous studies have shown a different effect of aluminum (Al) on bone metabolism in animals with chronic renal failure and conversely, positive osteogenic effects in animals with normal renal function. The aim of this study was to evaluate the effect of aluminum on bone metabolism in osteopenic rats. We studied male Wistar rats with severe osteopenia induced by adding NH4Cl (2%) to the drinking water over a 6-month period. The rats were divided into two groups and followed for 4 months. The Aluminum group (G1) received AlC13 intraperitoneally (10 mg/kg/5 days/week) (n = 8); the Control group (G2) did not receive any treatment after stopping the administration of NH4Cl (n = 5). In all animals we measured biochemical markers (serum Ca, P, Cr, Al, osteocalcin, hydroxyproline) as well as bone mineral density and bone histomorphometry (BV/TV, CTh, ObS/BS, OTh, and NOc/TV). Bone aluminum content, measured by atomic absorption spectrometry, was 101.6 +/- 13 microg/g in the Al overloaded group and 1.31 +/- 0.14 in controls. Bone mineral density, evaluated by dual X-ray absorptiometry (DXA) at the proximal extremity of the tibia was significantly higher in G1 (0.292 +/- 0.01 g/cm2 versus 0. 267 +/- 0.02 g/cm2). No significant differences were found between the biochemical markers. In the histomorphometric parameters we observed significant differences in G1 compared with G2: an increase in BV/TV (18.59 +/- 5.6 versus 7.69 +/- 3.08%) and in CTh (0.52 +/- 0.06 versus 0.36 +/- 0.07 mm) with a moderate increment of the osteoid thickness (14.05 +/- 4.72 versus 5.25 +/- 0.9 microm) (P < 0. 05). Changes in others parameters and the relationship between biochemical parameters of bone remodeling, Al, and histology were analyzed. These findings indicate that in rats with normal renal function, Al is able to induce bone formation even when osteopenia is present.
Gómez-Alonso
C
C
Bone and Mineral Research Unit, Metabolismo Oseo y Mineral, Instituto Reina Sofía de Investigación, Hospital Central de Asturias, C/ Julian Claveria s/n, 33006 Oviedo, Spain.
Menéndez-Rodríguez
P
P
Virgós-Soriano
M J
MJ
Fernández-Martín
J L
JL
Fernández-Coto
M T
MT
Cannata-Andía
J B
JB
D000535:Aluminum / Q000378:metabolism / Q000494:pharmacology*; D000643:Ammonium Chloride / Q000633:toxicity; D000818:Animals; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D007668:Kidney / Q000502:physiology*; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000378:metabolism; D008297:Male; D010012:Osteogenesis / Q000187:drug effects*; D011859:Radiography; D051381:Rats; D017208:Rats, Wistar; D013054:Spectrophotometry, Atomic; D013623:Tail / Q000000981:diagnostic imaging / Q000378:metabolism; D013977:Tibia / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology
D015415:Biomarkers; D000643:Ammonium Chloride; D000535:Aluminum